Supernus Pharmaceuticals
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average and near the bottom of the universe on momentum.
- Signal has read STRONG SELL for 3 weeks.
- Its last 5 Sell calls were followed by a 4% average decline over the next quarter.
- Recent price momentum is -37.9% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has fallen to 7.9% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-21 20:27 UTC
Data coverage: 6 of 6 factors. Missing data is not a zero score.
Valuation F
How expensive the stock is versus earnings, sales and its own 5-year history.
| Forward P/E | 80.3x | Better than 4% |
| Price / Sales | 7.1x | Better than 15% |
Growth C
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 2.5% | Better than 37% |
| Net income CAGR (3Y) | 11.4% | Better than 62% |
| Free cash flow CAGR (3Y) | -26.6% | Better than 14% |
Profitability C
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 89.6% | Better than 96% |
| Operating margin | -5.1% | Better than 17% |
| Net margin | -5.4% | Better than 19% |
| Return on equity | -3.7% | Better than 24% |
| Return on invested capital | -4.5% | Better than 22% |
Momentum C-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -37.6% | Better than 12% |
| 6-month return | -40.7% | Better than 12% |
| 12-month return (ex latest month) | -7.2% | Better than 25% |
| Distance below 52-week high | 13.9% | Better than 74% |
Financial Health A-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 1.9x | Better than 53% |
| Debt to assets | 2.8% | Better than 85% |
| Interest coverage | 2.1x | Better than 38% |
| Free cash flow / net income | 231.8% | Better than 81% |
Analyst View A-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 83.3% | Better than 63% |
| Upside to average target | 83.9% | Better than 79% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 28.35
- Open
- 28.39
- Day range
- 28.15 - 29.51
- Avg price
- 28.86
- Volume
- 2.83M
- Turnover
- 81.70M
- Turnover ratei
- 1.40%
- Volume ratioi
- 1.02
- Amplitudei
- 4.80%
- 52-week rangei
- 21.48 - 33.22
Valuation
- P/Ei
- -42.07
- P/E (TTM)i
- -37.64
- P/Bi
- 5.59
- EPSi
- -0.68
- Book value / shi
- 5.12
- Net profit
- -141.25M
- Net assets
- 1.06B
Share structure
- Market cap
- 5.94B
- Float capi
- 5.78B
- Shares out
- 207.72M
- Float sharesi
- 201.93M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
13.9% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+16.79M net over the window
Short interest
- Shares short
- 4.62M
- % of floati
- 7.93%
- Days to coveri
- 3.42
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Supernus Pharmaceuticals (SUPN)?
Supernus Pharmaceuticals last traded at 28.61. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Supernus Pharmaceuticals's market cap?
About 5.94B.
What is the P/E ratio of Supernus Pharmaceuticals?
The trailing twelve-month P/E is -37.64, below its own 5-year average of 84.23 — toward the bottom of its historical range (19.86% percentile). See the Valuation tab for the full history.
Does Supernus Pharmaceuticals pay a dividend?
Supernus Pharmaceuticals does not currently pay a regular dividend.
Is Supernus Pharmaceuticals a buy according to analysts?
The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 52.60, which implies 83.9% upside from the current price. This is not investment advice.
What is Supernus Pharmaceuticals's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Supernus Pharmaceuticals a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.
Quote time 2026-11-20 16:48:01 · For reference only, not investment advice and not tailored to your situation.
Supernus Pharmaceuticals discussion 0 comments